Company / Operating Cash Flow per Share
CRISPR Therapeutics AG Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$3.60
FY2025
5-year range
-$6.31 / $7.00
FY2021-FY2025
Trend
-116.1%
vs FY2024
Sector context
#183 of 212
Health Care
What the data says
CRISPR Therapeutics AG's operating cash flow per share of $-3.60 is lower than 86% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-6.31 in FY2022 to $7.00 in FY2021.
Based on SEC 10-K filings.
-3.60 in FY2025.
Declined from $-3.25 to $-3.60 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 212This company -$3.60 Sector average -$14.69
▼
+75.5% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 116.1% year-over-year.
- Ranks #183 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.60 | -116.1% |
| FY2024 | -$1.67 | +48.8% |
| FY2023 | -$3.25 | +48.5% |
| FY2022 | -$6.31 | -190.2% |
| FY2021 | $7.00 | +317.1% |
| FY2020 | -$3.22 | -395.0% |
| FY2019 | $1.09 | +183.9% |
| FY2018 | -$1.30 | -187.0% |
| FY2017 | $1.50 | +272.6% |
| FY2016 | -$0.87 | -107.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026